Mapping the Chemical Space of Synthetic and Natural Product Chelators.

Samuel V Feeney, Slade T Matthews, Rachel Codd

Abstract read

In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Samuel V FeeneySchool of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID https://orcid.org/0000-0002-9697-2992

Slade T MatthewsSydney Pharmacy School, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID https://orcid.org/0000-0002-1652-543X

Rachel CoddSchool of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.ORCID https://orcid.org/0000-0002-2703-883X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary metabolite natural products are recognized as having high structural diversity, with the associated property diversity resulting in their prevalent clinical use, compared to lower-diversity synthetic agents. It follows that subclasses of secondary metabolite natural products with useful applications, such as metal chelators (including siderophores), would have higher structural diversity compared to synthetic chelator counterparts, however, there are no quantitative measures to support this assumption. Chelators have wide use in applications across metal recovery and radiometal delivery, with growth in these sectors leading to expanded efforts to source new chelators. This motivated a quantitative analysis of the structural diversity of natural product and synthetic chelators. This work produced a data set of chelators (

Identifiers

PMID42729791

DOI10.1021/acsomega.6c06383

PMCPMC13563925

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.